Taysha Gene Therapies, Inc. SEC Filings

Taysha Gene Therapies (TSHA) filed a Form 144 reporting a proposed sale of 54,491 shares of common stock (RSU award) on 08/21/2025. The shares were a vested RSU grant settled in stock to the reporting person as consideration for continued employment. The broker listed is Maxim Group LLC and the sale is planned on Nasdaq. The filing shows an aggregate market value of $156,389.17 based on the proposed sale and lists 272,794,885 shares outstanding. The filer reports no other sales in the past three months.

Taysha Gene Therapies insider notice to sell 19,604 shares via Maxim Group under Rule 144. The filing reports a proposed sale of 19,604 shares of common stock with an aggregate market value of $56,263.48 based on the filer’s information. The shares represent vested RSU awards acquired and settled in stock on 08/21/2025; the stated consideration for those awards was the reporting person’s continued service as an employee. The filing lists total outstanding shares of 272,794,885 and identifies Nasdaq as the exchange for the approximate sale date of 08/21/2025. No other sales in the past three months were reported.

Taysha Gene Therapies, Inc. (TSHA) filing a Form 144 notifies the proposed sale of 57,054 shares of common stock through Maxim Group LLC on 08/21/2025 on Nasdaq. The filing shows these shares were acquired the same day as a vested RSU award from the issuer and settled in stock, with the stated consideration being the reporting person’s continued service as an employee. The filing reports no other sales in the past three months and includes the standard representation that the seller has no undisclosed material adverse information about the issuer.

Taysha Gene Therapies (TSHA) filing a Form 144 notifies intent to sell 27,590 shares of common stock through Maxim Group LLC on 08/21/2025 with an aggregate market value of $79,183.30. The shares were acquired as a RSU award and were vested and settled in stock on 08/21/2025, with the stated consideration being the reporting person’s continued service as an employee. The filing reports 272,794,885 shares outstanding and indicates no securities sold by the reporting person in the prior three months.

Taysha Gene Therapies (TSHA) filed a Form 144 reporting a proposed sale of 50,451 shares of common stock, representing a small fraction of the company's outstanding shares. The shares were issued as an RSU award and vested on 08/21/2025, with the reporting person stating the consideration for the grant was continued service as an employee. The proposed sale lists Maxim Group LLC as the broker and an aggregate market value of $144,794.37. The approximate date of sale and the acquisition/settlement date are both reported as 08/21/2025, and the securities are listed on Nasdaq. The filer reports no other securities sold in the past three months and affirms no undisclosed material adverse information.

RA Capital and affiliated persons reported a near-10% position in Taysha Gene Therapies (TSHA). The filing shows each Reporting Person beneficially owns 25,345,988 shares, representing 9.99% of the class as of June 30, 2025, limited by a Beneficial Ownership Blocker in pre-funded warrants. The Fund directly holds 23,555,648 shares and pre-funded warrants exercisable for up to 52,134,718 shares, but cannot exercise warrants that would raise ownership above the 9.99% threshold. RA Capital is the investment adviser with sole voting and dispositive power delegated by the Fund; Dr. Kolchinsky and Mr. Shah are identified as controlling persons.

RTW Investments, LP and Roderick Wong report beneficial ownership of 25,183,287 shares of Taysha Gene Therapies, Inc., representing approximately 9.99% of the outstanding common stock. The reported holdings reflect shared voting and shared dispositive power over the 25.18 million shares and include warrants to purchase 161,703 shares that were counted at their maximum exercisable amount but which cannot be exercised to increase beneficial ownership above the 9.99% threshold. The filing states these shares are held by RTW-managed funds and that RTW Master Fund Ltd. has the right to receive dividends or sale proceeds for more than 5% of the class. The filing is submitted on a Schedule 13G amendment and characterizes the position as held in the ordinary course of business.

Taysha Gene Therapies reported a strengthened balance sheet after a May 2025 underwritten offering that generated approximately $215.6 million in net proceeds, increasing cash and cash equivalents to $312.8 million and total assets to $333.3 million as of June 30, 2025. The company reported a net loss of $48.4 million for the six months ended June 30, 2025, which translates to a loss per share of $0.17 on a weighted-average share base of 283.7 million; research and development and general and administrative expenses totaled $52.5 million for the six-month period.

The company recognized $4.3 million of revenue related to Rett research and development activities in the six months, and deferred revenue related to the Astellas option totaled $5.5 million as of June 30, 2025. Taysha recorded the Trinity term loan at fair value and continues to mark the loan and a related success fee to market; the company stated it believes existing cash will be sufficient to fund planned operations for at least twelve months from issuance of these financial statements.